Axol Bioscience Ltd.

At Axol Bioscience, we place great value on collaboration, which is why we've enjoyed attending 15 international events in the first half of 2024, meeting up with existing partners, and initiating many new relationships with future collaborators. From SLAS and SOT to MPS, CHDI, and many others, we would like to thank the organizers for bringing together like-minded professionals with whom we've had great discussions and built valuable partnerships. Conferences help us understand the iPSC landscape, take a look at emerging trends and needs, let our scientists showcase their research, and do some important "team-building" (aka navigating the fun challenges of travel and international cuisine!). At each conference we've discussed our work with scientists and researchers to get their valuable feedback and invited them to join our growing iPSC community. We have a busy schedule ahead, so come and speak to our team at the upcoming events in H2, more details to follow! #H1Events #Collaboration #iPSCs #StemCells

Functional iPSC-derived cells and the standardization of Microphysiological Systems We continue to see expansion in the adoption and use of MPS as the industry incorporates these models into early pharmacological screening and drug discovery. As models become more complex. It's essential to drive standardization across the wide range of platforms in use. Standardization should focus on the cells and reagents used, including ensuring batch-to-batch consistency of functionality, with manufacturing at an industrial scale and the development of stable and well-characterized cell lines with the appropriate rights and consents. Axol Bioscience have over a decade of experience supplying high-quality products and services to biopharma organizations. Our Quality Management System drives quality and consistency within our organization and is the bedrock for our daily work. We therefore welcome the publication of the International Society for Stem Cell Research (ISSCR) Standards Document, and are pleased to report excellent compliance with each of its components - see our response to the document below. Contact us to talk about how Axol can power your MPS, click here: https://lnkd.in/eU7ftJKw For more information, click here: https://lnkd.in/eDRSSbAN #iPSCs #DrugDiscovery #ISSCR #BetterHumanDiseaseModels #OrganOnChip

As iPSC leaders, we've applied our decade of expertise to become the first choice for AD researchers looking to benefit from iPSC technology. Our new 2024 "Focus on Alzheimer's Disease" document highlights the latest developments in iPSC-derived Alzheimer's Disease modelling, and gives information on the products and services we provide to power AD research. Read more about our new document and download it here: https://hubs.la/Q02HXYyG0 We can power your AD research with: • axoLines™: we've done the hard work developing 7 iPSC lines (axoLines) reprogrammed from patients with AD. These axoLines can be used for custom differentiation to endpoint neurons and neuroinflammatory cells to build advanced in vitro AD models. • axoCells™: fuel your AD research with functional cells manufactured in our ISO 9001-accredited production facility • axoServices™: let us do the "heavy lifting" with a comprehensive suite of outsourced lab services, including differentiation, gene editing and AD compound screening • axoModels™: let's collaborate as we work to develop a "clinical trial in a dish" (CTIAD) model If you have any questions or would like to discuss a project, email us at [email protected] and let us know what we can do to help! #iPSCs #AD #StemCells #Alzheimer's Disease

If you're looking to build a complex tri-culture model for neurotoxicity screening, we can supply you with high-quality, functional cortical excitatory neurons. Let's have a conversation! Take a look below to see the cortical excitatory neuron chapter of our axoCells™ Catalog, or click here to download the full catalog: https://lnkd.in/epUnnZWt axoCells cortical excitatory neurons are assay-ready in just 20 days, and are frequently used to fuel in vitro neuroscience models (including Alzheimer's disease) in culture with other neuronal and neuroinflammatory cells. To see how we validated an axoModel™ for use in human-relevant drug discovery and neurotoxicity screening, download our poster, "Validation of a cortical tri-culture axoModel for in vitro compound screening a blinded compound study": https://lnkd.in/eswEZxP2 #iPSCs #CorticalExcitatoryNeurons #AlzheimersDisease #CoCulture #StemCells

iPSC-derived cells for Microphysiological Systems We attended the MPS World summit in Seattle in June, to discuss the advances and challenges in the field with other pioneers within the MPS community. It's great to be part of such an engaging and positive community, with a collaborative culture which enables rapid scientific progress, implements scientific developments and ensures global harmonization. To support this vibrant MPS community, we recently created our new catalog, "Functional iPSC-derived cells for MPS systems". Download the catalog to find out : • How your platforms can be powered by axoCells™, using our 7 key neurons/neuroinflammatory cells and 2 key cardiac cells, manufactured under ISO 9001 regulations • The investment we've made into our production capabilities for bulk volume, functional iPSC product manufacturing with excellent batch-to-batch consistency • How we collaboratively build model systems with integration for higher throughput platforms (including MPS systems) Click here to download the "Functional iPSC-derived cells for MPS systems" catalog: https://hubs.la/Q02HMpZh0 If you're looking for functional and high-quality iPSC-derived cells for your MPS systems? Let's have a conversation! Get in touch at [email protected] for more information. #iPSCs #MPS #MicrophysiologicalSystems #microfluidics #StemCells

"2024 is shaping up to be the year of iPSCs". My H1 Report - by Liam Taylor, CEO, Axol Bioscience With advancements in iPSC technology, global events, exciting collaborations and a vision for the future of human stem cell applications, it's an exciting time for us at Axol. Click here to read Liam's reflections on the major highlights from the first six months of the year: https://hubs.la/Q02HM0NX0 If you'd like to access industry-leading iPSC technology for your in vitro research, make sure to contact [email protected].

We think TREM2 is a promising avenue for Alzheimer's Disease research and drug discovery- but what do you think? Alzheimer's Disease is the most common form of dementia worldwide, affecting over 40 million people. Yet despite this prevalence, we still have limited treatments and a staggering 99.6% failure rate for promising pre-clinical therapies. Human iPSC-based Alzheimer's Disease (AD) models could help us to tackle this challenge by providing more human-relevant disease models that incorporate patient-derived mutations for research and drug discovery. One gene that is of increasing interest to AD researchers is TREM2 (triggering receptor expressed on myeloid cells 2) which plays an important role in the function of the brain's main neuroinflammatory cell, microglia. TREM2 mutations have been linked to the development of abnormal microglial behavior, potentially driving neurodegenerative diseases including AD. At Axol Bioscience, we're excited about the potential of TREM2 for AD drug discovery and have been exploring it as part of our wider AD disease model focus. We've therefore produced a discussion document to outline: • Why TREM2 could be a major target for AD drug discovery • The work we've done investigating TREM2 mutations in microglia • How we can support researchers looking to build in vitro TREM2 AD models Click here to access our discussion document: https://hubs.la/Q02HBF1h0 If you'd like to discuss a project, get in contact at [email protected] #iPSCs #microglia #TREM2 #AlzheimersDisease #DrugDiscovery

Missed The Physiology Society Conference this month? We made our poster available for download! Our Senior Scientific Support Manager Dr Steven Broadbent presented a poster titled "Evaluation of a new media designed to drive improved maturity of iPSC-derived cardiomyocytes for cardiac disease, cardiotoxicity and drug screening". With market-leading iPSC products and services for neuroscience and cardiovascular research and toxicity screening, Axol Bioscience has become the first choice for in vitro research. Get in touch with us at [email protected] for a discussion about your research needs. Click here to download the poster: https://hubs.la/Q02HBhDZ0 #iPSCs #PhySoc #StemCells #biopharma

If you're looking for high-quality, functional sensory neurons to fuel your in vitro models, we can help. We've spent the last 10 years developing our manufacturing capabilities to become the first choice for consistent, functionally relevant iPSC-derived sensory neurons to power robust cosmetic toxicology and pain/touch models. In this excerpt from our Sensory Neurons iPSC tech help clinic, Axol Strategic Partnership Manager Stuart Prime talks us through some of the functional characterization we've performed on our axoCells™ Sensory Neurons using a Multi-Electrode Array (MEA) system. You can explore this data in the sensory neuron section of our axoCells Catalog: https://hubs.la/Q02Hpkq20 Click here to watch the full webinar: https://hubs.la/Q02HpjTG0 #iPSCs #SensoryNeurons #DrugDiscovery #CosmeticToxicology #PainResearch #MultiElectrodeArray

axoCells™ microglia - the first choice for functional human iPSC-derived cells to power your in vitro neurodegeneration models. When you're looking for a high-quality source of iPSC-derived microglia, what does better look like? Correct morphology? Key markers? Functional relevance across multiple assays? Characterization in advanced in vitro models? How about all of the above?! We've spent the last decade developing our manufacturing capabilities to produce robust, consistent, functionally-relevant axoCells iPSC-derived microglia. The key features that can supercharge your research include: • Rapid maturation: Assay ready in just 7 days • Phenotypic relevance: Extensive characterization including morphology and key marker expression (including IBA-1, TMEM119 and P2RY12) • Functional relevance: Validation of functional activity across multiple assays including phagocytosis, chemotaxis and cytokine release • Confidence: Manufactured in our ISO 9001-accredited production facility with excellent ISSCR compliance, enabling you to confidently carry out your in vitro workflow Our axoCells microglia have multiple applications including in vitro models of Alzheimer’s Disease and ALS. They can be used in a variety of platforms, from simple monoculture compound screens up to complex co-culture models, microfluidics systems or organ-on-chip models. As part of our axoServices™ offering, we can also develop microglia compound screening models to run in-house or tech transfer to customers. Explore the data, applications and features in our 2024 axoCells Microglia eBook: https://hubs.la/Q02Hcqc-0 Looking for advice, support or products for your in vitro research? Get in touch at [email protected] #iPSCs #Microglia #AlzheimersDisease #ALS #phagocytosis